MSP 1014
Alternative Names: MSP-1014; MSP-1014.OXLatest Information Update: 09 Jan 2024
At a glance
- Originator Mindset Pharma
- Developer Otsuka America Pharmaceutical
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
- Preclinical Anxiety disorders; Depressive disorders
Most Recent Events
- 01 Jan 2024 Mindset Pharma has been acquired and merged into Otsuka America Pharmaceutical
- 20 Jan 2023 Mindset Pharma receives patent allowance for MSP 1014, its backup MSP 1009 and additional prodrug candidates classified under family I in US
- 30 Nov 2022 Pharmacodynamics data from a preclinical studies in Anxiety and Depressive disorders released by Mindset Pharma